Autosomal Recessive Spastic Paraplegia Type 78 (SPG78)

Autosomal recessive spastic paraplegia type 78 is a rare genetic nerve disease. It mainly affects the long motor pathways that run from the brain to the legs. The core signs are gradually increasing stiffness (spasticity) and weakness in the lower limbs. People often notice trouble with walking first. Over time, balance gets worse. Some people also have problems from the cerebellum, such as slurred speech, eye movement problems, and unsteady, wide-based walking. Brain scans may show shrinkage (atrophy) of the cerebellum. A few people also develop memory or thinking problems. The age at which symptoms start is usually in late teens or adulthood, and the course is slowly progressive. The condition is inherited in an autosomal recessive way, which means both copies of the same gene are changed. NCBI+1

SPG78 is an inherited movement disorder. Two changed copies of the same gene (ATP13A2) are passed from parents to a child (autosomal recessive). This gene helps the brain’s cells manage “recycling” inside small sacs called lysosomes and helps move tiny positively charged molecules called polyamines. When the gene does not work, the recycling system is stressed, waste builds up, and nerve cells in the long movement pathways that control the legs are affected first. Over time, walking becomes stiff and tiring. Some people also develop other problems such as slow movements, eye movement limits, or thinking changes. There is no single test that fixes it; instead, a team uses therapy, medications, and practical supports to keep you active and safe. PMC+2PMC+2

ATP13A2 is a lysosomal P-type ATPase that moves polyamines and helps keep cell recycling and energy systems stable. When it fails, cells show lysosome stress, oxidative stress, and protein disposal problems—mechanisms that also appear in related conditions such as Kufor-Rakeb syndrome. Understanding this biology explains why therapy focuses on movement quality, spasticity reduction, and fall prevention while research explores lysosome-targeted strategies. PMC+2PNAS+2

SPG78 is caused by harmful changes (biallelic mutations) in a gene called ATP13A2. This gene makes a membrane “pump” (a P-type ATPase) in the lysosome, a recycling compartment in cells. ATP13A2’s normal job is to move small positively charged molecules called polyamines out of the lysosome into the cytosol. When ATP13A2 does not work, polyamines become unbalanced, lysosomes do not clear waste well, and mitochondria may become stressed. This can injure long motor pathways and the cerebellum. PMC+1

Scientists first linked ATP13A2 to complex forms of hereditary spastic paraplegia in 2016–2017, and since then multiple families have been reported worldwide. The clinical picture can vary. Some people show mainly leg spasticity. Others also have ataxia (incoordination), eye movement abnormalities, neuropathy, or mild cognitive changes. This range reflects how ATP13A2 problems disturb lysosomes and mitochondria in different nerve cell types. OUP Academic+1

---

Other names

This condition is also called: Spastic paraplegia 78 (SPG78), Autosomal recessive spastic paraplegia-78, and Hereditary spastic paraplegia type 78. In databases you may see OMIM 617225 and the gene ATP13A2 (OMIM *610513). MalaCards+1

---

Types

Doctors often describe SPG78 using simple clinical groupings. These are not different diseases, just patterns seen across patients.

1) “Pure” spastic paraplegia pattern.
People mainly have stiff, weak legs, brisk reflexes, and toe-upgoing (Babinski) responses. Walking becomes slow and effortful. Bladder urgency may appear. Coordination and thinking are mostly preserved. medlink.com

2) “Complicated” spastic paraplegia pattern.
Leg spasticity occurs together with other neurological signs. The most frequent are cerebellar signs (ataxia, slurred speech, abnormal eye movements) and sometimes mild thinking changes. Peripheral nerve involvement (axonal neuropathy) can also appear. Brain MRI may show cerebellar atrophy. orpha.net+1

3) Overlap with ATP13A2 spectrum.
The same gene can cause other disorders, such as Kufor-Rakeb syndrome (a form of early-onset parkinsonism). A few SPG78 patients show limited parkinsonian features like slowness or rigidity, but SPG78 typically starts later and is dominated by spastic paraplegia. PubMed

---

Causes

1. Biallelic ATP13A2 mutations.
   The root cause is having two harmful changes—one in each copy—of the ATP13A2 gene. This blocks the pump’s normal action in lysosomes. PMC

2. Loss of lysosomal polyamine export.
   ATP13A2 normally exports polyamines (like spermine) from the lysosome to the cytosol. Loss of function traps polyamines, causing imbalance. PMC

3. Lysosomal dysfunction.
   When ATP13A2 fails, lysosomes cannot handle waste and damaged proteins well. This stresses neurons over time. PNAS

4. Mitochondrial stress and oxidative injury.
   ATP13A2 loss increases reactive oxygen species and disrupts mitochondrial energy handling, harming long motor pathways. PNAS

5. Altered zinc handling.
   Cells without ATP13A2 show zinc dyshomeostasis, which can be toxic to neurons. PMC

6. Impaired autophagy/mitophagy.
   Defective ATP13A2 reduces fusion of autophagosomes with lysosomes, so damaged mitochondria and proteins build up. rupress.org

7. α-synuclein accumulation (subset).
   Poor lysosomal clearance can promote α-synuclein clumping, which adds cellular stress in some patients. Aligning Science Across Parkinson’s

8. Disrupted polyamine homeostasis in neurons.
   Polyamines help stabilize RNA, membranes, and ion channels. Their imbalance can disturb neuronal signaling. Nature

9. Axonal degeneration of corticospinal tracts.
   Long motor axons are vulnerable to energy and waste-clearance problems, leading to spastic weakness. medlink.com

10. Cerebellar neuron vulnerability.
    Cerebellar circuits rely on tight metabolic control; lysosomal/mitochondrial dysfunction can shrink the cerebellum. MalaCards

11. Peripheral axonal neuropathy (some patients).
    SPG78 can include axonal motor and sensory neuropathy that worsens gait and balance. MalaCards

12. Transcript/protein instability of mutant ATP13A2.
    Several disease variants destabilize ATP13A2 mRNA or protein, sharply lowering pump activity. PubMed

13. Abnormal intracellular localization of mutant protein.
    Some variants mislocalize ATP13A2 away from lysosomes, so it cannot do its job. OUP Academic

14. Defective catalytic autophosphorylation.
    Pathogenic variants can disrupt the enzyme’s pumping cycle, halting transport. OUP Academic

15. K+-linked transport changes (research area).
    Recent work suggests ATP13A2 may couple to K+ in lysosomes, and disturbed K+ handling could add stress. Nature

16. Genetic founder effects in some families.
    Clusters of cases in extended families reflect inherited shared variants. PMC

17. Compound heterozygosity.
    Two different harmful variants (one from each parent) can combine to cause disease. PMC

18. Frameshift or nonsense variants.
    These create truncated proteins that lack normal function. PubMed

19. Missense variants affecting structure.
    Single amino-acid changes can distort the transporter’s shape and stop polyamine export. PubMed

20. Splice-site alterations.
    Some variants alter splicing and reduce normal ATP13A2 production. neurology.org

---

Symptoms

1. Stiff legs (spasticity).
   Muscles feel tight. Knees resist bending. Walking feels effortful and jerky. NCBI

2. Weakness of the lower limbs.
   Legs tire easily, stairs feel heavy, and standing up can be slow. NCBI

3. Frequent tripping or falls.
   Toe dragging and poor foot clearance make small obstacles risky. medlink.com

4. Brisk reflexes and Babinski signs.
   Tapping the knee gives big kicks; scraping the sole makes the big toe go up. These are upper motor neuron signs. medlink.com

5. Gait problems.
   People take short, stiff steps and need more effort to balance. Walking gets slower over time. orpha.net

6. Muscle spasms or cramps.
   Spastic muscles can twitch or cramp, especially at night or with sudden movement. medlink.com

7. Urinary urgency (sometimes).
   Overactive bladder can come with upper motor neuron disorders. medlink.com

8. Slurred or scanning speech (dysarthria).
   Cerebellar involvement can make speech uneven or shaky. MalaCards

9. Unsteady, wide-based walk (ataxia).
   The cerebellum helps coordinate movement; when it fails, balance worsens. orpha.net

10. Abnormal eye movements.
    People may have saccadic pursuit, nystagmus, or limited vertical gaze; these reflect brainstem/cerebellar pathways. MalaCards

11. Peripheral neuropathy (subset).
    Numbness, burning, or reduced vibration sense can appear with axonal neuropathy. MalaCards

12. Mild cognitive changes (some).
    A few people report slower thinking or memory lapses; rarely, dementia. NCBI

13. Fatigue.
    Energy demands rise as walking becomes harder; mitochondrial stress may add to tiredness. PNAS

14. Parkinsonian features (rare overlap).
    Slow movement or rigidity can occur in the ATP13A2 spectrum but are not the main SPG78 picture. PubMed

15. Progression over years.
    Symptoms usually worsen gradually; some people may later need a cane or wheelchair. NCBI

---

Diagnostic tests

A) Physical examination

1. Standard neurological exam.
   The doctor checks tone, power, coordination, and sensation. Spasticity and weakness in the legs point to corticospinal tract disease. medlink.com

2. Deep tendon reflexes and plantar responses.
   Brisk knee/ankle jerks and an upgoing big toe (Babinski) support an upper motor neuron problem. medlink.com

3. Gait and balance evaluation.
   Observation of stride length, foot clearance, scissoring, and need for support helps stage severity. orpha.net

4. Cerebellar signs on exam.
   Speech clarity, eye movements, finger-nose testing, and heel-knee-shin maneuvers reveal ataxia common in SPG78. MalaCards

B) Manual/bedside functional tests

5. Heel-to-shin test.
   Sliding the heel down the opposite shin checks leg coordination; wobble or overshoot suggests cerebellar involvement. medlink.com

6. Rapid alternating movements.
   Fast foot taps or hand flips test timing; irregular rhythm supports cerebellar dysfunction. medlink.com

7. Timed Up-and-Go (TUG) or 10-meter walk.
   These quick measures track walking speed and fall risk as spasticity progresses. medlink.com

8. Pull test (postural stability).
   A sudden backward tug checks balance recovery; impaired response warns of falls in complex cases. medlink.com

C) Laboratory and pathological tests

9. Genetic testing for ATP13A2.
   Targeted sequencing or an exome panel confirms biallelic pathogenic variants and secures the diagnosis. PMC

10. Segregation analysis and genetic counseling.
    Testing parents/siblings clarifies autosomal recessive inheritance and recurrence risk. PMC

11. Rule-out blood tests (B12, copper, thyroid, HIV, HTLV-1, etc.).
    These exclude treatable mimics of spastic paraparesis and ataxia. medlink.com

12. Metabolic screens when indicated.
    Tests such as lactate, very-long-chain fatty acids, or celiac serology can exclude other rare causes if clues suggest them. medlink.com

13. Exploratory polyamine profiling (research).
    Because ATP13A2 moves polyamines, research labs may study polyamine patterns; this is not yet standard care. Nature

14. Trace metal studies (supportive, not diagnostic).
    Zinc or manganese levels are sometimes checked in research settings given ATP13A2-linked ion stress. Results do not confirm SPG78 but can inform counseling. PMC

D) Electrodiagnostic tests

15. Nerve conduction studies (NCS).
    Some patients show axonal sensory-motor neuropathy that contributes to gait difficulty. NCS documents the pattern. MalaCards

16. Electromyography (EMG).
    EMG helps separate spasticity (central) from lower motor neuron disease and can reveal neuropathic changes. medlink.com

17. Evoked potentials (MEP/SEP) when available.
    These measure how well signals travel in the corticospinal and sensory pathways and may show slowed conduction. medlink.com

E) Imaging tests

18. Brain MRI.
    MRI often shows cerebellar atrophy and sometimes mild cerebral atrophy; these support the “complicated” HSP pattern. MalaCards

19. Spine MRI.
    This rules out spinal cord compression or inflammation that could mimic spastic paraparesis. medlink.com

20. Dopamine transporter imaging (DaTscan) in selected cases.
    If parkinsonian features appear, DaTscan or related studies can help distinguish overlap with ATP13A2-related parkinsonism. PubMed

Non-pharmacological treatments (therapies & other supports)

1. Individualized Physiotherapy (PT) program
   Description (≈150 words): A personalized PT plan combines stretching, strengthening, balance drills, treadmill or over-ground gait practice, and task-specific exercises. Sessions are adjusted to your stiffness level and fatigue, with home practice between visits. Therapists also teach posture, transfers, safe turns, and how to recover from a stumble. Programs often include warm-up, hip and calf stretches, core and glute strengthening, step training, and endurance (walking, cycling, or pool). Regular reassessment keeps goals realistic and prevents over-use injuries.
   Purpose: Reduce spasticity, maintain range of motion, improve gait efficiency, prevent contractures, cut fall risk, and support confidence.
   Mechanism: Repeated, graded practice remodels neural circuits (neuroplasticity), normalizes muscle length–tension, and improves reciprocal activation of agonist–antagonist muscles; aerobic work supports fatigue resistance. PMC+2PMC+2

2. Stretching & positioning routine
   Description: Daily hamstring, hip flexor, adductor, and calf stretches (held 30–60 seconds; several repetitions) plus night positioning (e.g., pillows, ankle neutral splints) keep muscles long and joints aligned.
   Purpose: Ease stiffness and delay fixed contractures that worsen walking and pain.
   Mechanism: Slow, sustained stretch reduces reflex hyperexcitability and improves muscle–tendon compliance, lowering passive resistance to movement. Physiopedia

3. Task-oriented gait training (including treadmill, C-Mill/obstacle training)
   Description: Walking practice with variable speeds, step targets, obstacles, and dual-task drills builds adaptable walking. Instrumented treadmills (e.g., C-Mill) can project stepping targets and perturbations in supervised blocks.
   Purpose: Improve step length, foot clearance, turning, and safety.
   Mechanism: Task-specific repetition strengthens central gait patterns and improves anticipatory/postural control. BioMed Central

4. Aquatic therapy
   Description: Warm-water walking, cycling, and balance in chest-deep pools reduce load on joints and dampen spasticity so people can practice longer with less pain.
   Purpose: Build endurance and confidence and rehearse movement patterns safely.
   Mechanism: Buoyancy and warmth reduce muscle spindle activity; water resistance provides gentle strengthening. PMC

5. Strength training (glutes, hip abductors, dorsiflexors, core)
   Description: Low-to-moderate resistance, 2–3 days/week, emphasizing form and quality rather than maximal loads.
   Purpose: Counter disuse weakness and improve push-off, step clearance, and trunk stability.
   Mechanism: Hypertrophy and motor unit recruitment improve force production and gait stability; stronger antagonists can help modulate spastic agonists. PMC

6. Balance and falls-prevention program
   Description: Exercises like tandem stance, weight shifts, reactive stepping, and dual-task balance, with home safety checks (lighting, rugs, rails).
   Purpose: Reduce falls and injuries, maintain independence.
   Mechanism: Trains vestibular, visual, and proprioceptive integration and rapid protective stepping. PMC

7. Occupational therapy (OT)
   Description: OT addresses dressing, bathing, transfers, kitchen tasks, workplace ergonomics, and energy conservation, including adaptive tools and home modifications.
   Purpose: Keep daily activities safe and efficient.
   Mechanism: Task simplification and assistive devices reduce effort and spasticity triggers during tasks. PMC

8. Orthoses and footwear
   Description: Ankle-foot orthoses (AFOs), night splints, shoe wedges, and rocker-bottom shoes optimize foot position and toe clearance.
   Purpose: Improve gait efficiency and reduce tripping.
   Mechanism: External alignment lowers abnormal torque and reflex-mediated co-contraction. PMC

9. Spasticity self-management (heat, positioning, trigger control)
   Description: Heat packs, slow breathing, avoiding sudden stretch, and planning rest after exertion.
   Purpose: Lessen daily spasticity spikes and cramps.
   Mechanism: Reduces muscle spindle sensitivity and sympathetic arousal that amplifies tone. PMC

10. Dry needling or focal physical agent modalities (by trained clinicians)
    Description: Carefully applied dry needling and modalities (TENS, NMES) can be adjuncts for focal hypertonicity.
    Purpose: Short-term tone relief and improved range for therapy windows.
    Mechanism: Alters local motor end-plate activity and pain gating, facilitating stretch. HSP Research Foundation

11. Bladder training & pelvic floor therapy
    Description: Timed voiding, pelvic floor relaxation/activation, hydration scheduling, and constipation management.
    Purpose: Reduce urgency, frequency, and leakage common in HSP.
    Mechanism: Behavioral retraining and pelvic floor coordination reduce detrusor overactivity. PMC

12. Speech-language therapy (if dysarthria or swallowing issues)
    Description: Voice, breath support, pacing strategies; swallow safety education.
    Purpose: Clearer speech and safer swallowing when involved.
    Mechanism: Targets neuromuscular coordination and compensations. PMC

13. Cognitive and mental-health care
    Description: Screening for anxiety/depression; CBT, counseling, or group support.
    Purpose: Improve coping, adherence, and quality of life.
    Mechanism: Behavioral therapy reduces avoidance, improves sleep, and pain coping. PMC

14. Fatigue management & energy conservation
    Description: Plan high-effort tasks after rest, break tasks into chunks, sit when possible, and schedule therapy earlier in the day.
    Purpose: Maintain participation without over-fatigue.
    Mechanism: Balances activity/rest to limit spasticity amplification from exhaustion. sp-foundation.org

15. Assistive mobility (canes, walkers, wheeled devices)
    Description: Properly fitted devices for community distances or uneven ground.
    Purpose: Safety, speed, and participation.
    Mechanism: Enlarges base of support and reduces demand on antigravity muscles. PMC

16. Home and workplace modifications
    Description: Ramps, rails, shower chairs, raised toilet seats, sit–stand desks.
    Purpose: Reduce fall risk and effort; keep productivity.
    Mechanism: Environmental fit minimizes hazardous leverage and sudden stretches. PMC

17. Caregiver education
    Description: Safe transfers, cueing for turns, protecting joints, emergency fall plan.
    Purpose: Prevent injuries and burnout.
    Mechanism: Knowledge reduces unsafe handling and stress-triggered spasticity. PMC

18. Regular orthopedic/rehab surveillance
    Description: Periodic checks for contractures, scoliosis, hip/knee alignment.
    Purpose: Early detection allows timely splinting, injections, or surgery when needed.
    Mechanism: Prevents fixed deformity and preserves gait efficiency. PMC

19. Intrathecal Baclofen (ITB) candidacy evaluation (pre-surgical)
    Description: Screening bolus and functional goals discussion to see if a pump could help severe, generalized spasticity that resists other measures.
    Purpose: Identify those who may benefit from surgical ITB.
    Mechanism: Direct spinal GABA-B agonism with lower systemic effects. PMC

20. Multidisciplinary HSP clinic follow-up
    Description: Coordinated neurology, rehab, urology, mental health, and genetics visits.
    Purpose: Keep care integrated and proactive.
    Mechanism: Team care matches evolving needs and reduces delays. ScienceDirect

---

Drug treatments

Important: No drug is FDA-approved specifically for SPG78. The following medicines are commonly used to treat symptoms such as spasticity, cramps, pain, bladder urgency, mood, and associated parkinsonism. Doses are typical label ranges for their approved indications; final dosing must be individualized by a clinician who knows you, and off-label use is common in rare diseases.

1. Baclofen (oral) – GABA-B agonist for spasticity
   Description (≈150 words): Oral baclofen reduces stretch-reflex overactivity and spasm frequency in many upper-motor-neuron syndromes. Slow titration helps balance tone relief and side effects (sleepiness, dizziness, weakness). Avoid abrupt stop because withdrawal can cause severe rebound spasticity, fever, or seizures.
   Class: Antispasticity (GABA-B agonist).
   Dosage/Time: Start low (e.g., 5 mg 3×/day) and titrate; individualized max per label/clinician.
   Purpose: Reduce generalized spasticity and spasms to improve comfort and therapy participation.
   Mechanism: Activates spinal GABA-B receptors to inhibit excitatory neurotransmission in reflex arcs.
   Side effects: Sedation, weakness, dizziness; serious withdrawal if abruptly stopped. FDA Access Data

2. Tizanidine – central α2-agonist for spasticity
   Description: Short-acting antispasticity option useful for evening or activity-timed dosing; monitor for hypotension and liver enzymes.
   Class: Antispasticity (α2-adrenergic agonist).
   Dosage/Time: Titrate in divided doses.
   Purpose/Mechanism: Presynaptic inhibition reduces polysynaptic spinal transmission.
   Side effects: Sleepiness, dry mouth, hypotension, LFT elevations. FDA Access Data

3. Dantrolene – peripheral muscle relaxant
   Description: Reduces skeletal muscle contraction by acting on calcium release in the sarcoplasmic reticulum; consider if central agents poorly tolerated.
   Class: Direct-acting antispasmodic.
   Dosage/Time: Titrate; monitor liver function.
   Side effects: Weakness, fatigue, hepatotoxicity (rare). FDA Access Data

4. OnabotulinumtoxinA (BOTOX®) for focal spasticity
   Description: Targeted injections into over-active muscles (e.g., adductors, calves) reduce tone for ~3 months, enabling better stretching and gait training.
   Class: Neuromuscular blocking toxin (local).
   Dosage/Time: Per pattern; repeat ~q12 weeks.
   Mechanism: Blocks presynaptic acetylcholine release at NMJ.
   Side effects: Local weakness, pain; systemic effects rare. FDA Access Data

5. IncobotulinumtoxinA (XEOMIN®) – focal spasticity alternative
   Similar indications/mechanism; different formulation/dosing guidance. FDA Access Data

6. AbobotulinumtoxinA (Dysport®) – focal spasticity option
   Useful when larger muscle groups targeted; dosing units are not interchangeable among toxins. FDA Access Data+1

7. Intrathecal Baclofen (Gablofen®; Lioresal® Intrathecal) – pump therapy
   Description: For severe, widespread spasticity unresponsive to oral meds and therapy. Requires surgical pump and close follow-up.
   Class: Antispasticity via spinal delivery.
   Dosage/Time: Continuous infusion; individualized; avoid abrupt interruption.
   Side effects: Over-relaxation, hypotonia, catheter complications; withdrawal is an emergency. FDA Access Data+2FDA Access Data+2

8. Gabapentin – neuropathic pain, cramps
   Class: α2δ calcium-channel modulator.
   Dosage/Time: Titrate; renal dosing.
   Purpose/Mechanism: Dampens excitatory neurotransmission and ectopic firing; can reduce neuropathic burning or paresthesias that worsen spasticity experience.
   Side effects: Drowsiness, dizziness, ataxia. FDA Access Data

9. Pregabalin – neuropathic pain, sleep benefit
   Similar to gabapentin with different kinetics and simpler titration; monitor for edema and sedation. FDA Access Data

10. Duloxetine – neuropathic pain and mood
    Class: SNRI.
    Dosage/Time: Usually 30–60 mg/day; titrate.
    Purpose: Treat co-existing neuropathic pain and depression/anxiety common in chronic disability.
    Mechanism: Enhances descending inhibitory pain pathways.
    Side effects: Nausea, dry mouth, BP changes; taper to avoid discontinuation syndrome. FDA Access Data

11. Amitriptyline – pain, sleep (night dosing)
    Class: TCA.
    Mechanism: Noradrenergic/serotonergic reuptake inhibition; anticholinergic effects.
    Cautions: Cardiac conduction risk; next-day sedation. FDA Access Data+1

12. Dalfampridine (Ampyra®) – gait speed in MS (sometimes used off-label in HSP)
    Class: Potassium-channel blocker.
    Dosage: 10 mg twice daily; avoid in seizure or significant renal impairment.
    Rationale in HSP: May enhance conduction in demyelinated/compromised pathways, occasionally trialed to improve walking speed. Note: FDA approval is for MS; any HSP use is off-label and clinician-judged. FDA Access Data

13. Oxybutynin – bladder urgency/overactivity
    Class: Antimuscarinic.
    Mechanism: Reduces detrusor contractions; improve continence.
    Side effects: Dry mouth, constipation, cognitive effects in sensitive patients. FDA Access Data+1

14. Tolterodine / Tolterodine LA – bladder urgency alternative
    Mechanism: Antimuscarinic with different tolerability for some.
    Notes: Dose adjust in hepatic/renal impairment and CYP3A4 interactions. FDA Access Data+2FDA Access Data+2

15. Mirabegron (Myrbetriq®) – β3-agonist for overactive bladder
    Mechanism: Relaxes detrusor without anticholinergic effects; monitor BP and interactions.
    Use: Alone or with low-dose antimuscarinic if needed. FDA Access Data+1

16. Sertraline (or other SSRI) – depression/anxiety
    Rationale: Treating mood symptoms improves participation in rehab and sleep.
    Cautions: Titrate; monitor for activation and GI effects; taper to stop. FDA Access Data+1

17. Clonazepam (night cramps, myoclonus, severe spasms as short-term adjunct)
    Mechanism: GABA-A potentiation; may aid severe nocturnal spasms but risks sedation and dependence—use cautiously. FDA Access Data

18. Levodopa/carbidopa – if parkinsonism present in SPG78
    Mechanism: Replaces dopamine; may help bradykinesia/rigidity in ATP13A2-related phenotypes.
    Notes: Start low; watch for nausea, orthostasis, dyskinesia. FDA Access Data+1

19. Trihexyphenidyl – dystonia/rigidity adjunct (selected patients)
    Mechanism: Central anticholinergic; may reduce dystonia but can impair cognition and cause dry mouth/blurred vision—careful selection. FDA Access Data+1

20. Amantadine / Amantadine ER (Gocovri®) – fatigue, dyskinesia, gait initiation (selected cases)
    Mechanism: NMDA antagonism and dopaminergic effects; monitor for insomnia, livedo, hallucinations. FDA Access Data+1

---

Dietary molecular supplements

Evidence for supplements in SPG78 is indirect. Use only with clinician guidance, especially if you take prescription drugs.

1. Vitamin D
   Description (≈150 words): Many adults with neurologic disability have low vitamin D. Restoring low levels supports bone health and may help muscle performance in deficiency states.
   Dosage: Typically 800–2000 IU/day or as prescribed to reach normal 25-OH-D.
   Function/Mechanism: Genomic effects in muscle; improves calcium handling and may aid strength in deficient people. PubMed+1

2. Vitamin B12
   Description: Correcting B12 deficiency protects nerve health and prevents neuropathy and cognitive issues.
   Dosage: Oral 1,000 µg/day or periodic injections per labs.
   Mechanism: Cofactor in myelin and DNA synthesis; deficiency causes axonal neuropathy/myelopathy. PMC+1

3. Omega-3 fatty acids (EPA/DHA)
   Description: May help systemic inflammation and general cardiometabolic health; neuroinflammation modulation is biologically plausible.
   Dosage: Often 1–2 g/day combined EPA+DHA (food or capsules).
   Mechanism: Resolvin production, membrane effects, gene regulation in immune pathways. PMC+1

4. Coenzyme Q10
   Description: Mitochondrial cofactor; explored in neurodegenerative disorders.
   Dosage: 100–300 mg/day (with fat-containing meal).
   Mechanism: Electron transport/antioxidant roles; may reduce oxidative stress burden. PMC+1

5. Alpha-lipoic acid
   Description: Antioxidant used in diabetic neuropathy studies; evidence mixed but may help neuropathic symptoms in some.
   Dosage: 300–600 mg/day; monitor glucose and GI tolerance.
   Mechanism: Redox modulation and improved microcirculation in nerves. PMC+1

6. Magnesium (as glycinate/citrate)
   Description: Helpful for cramps in some people; avoid excessive doses if renal disease.
   Dosage: 200–400 mg elemental/day.
   Mechanism: NMDA modulation and membrane stabilization (indirect evidence). PMC

7. Creatine monohydrate
   Description: May support short-burst muscle performance in neuromuscular conditions; ensure adequate hydration.
   Dosage: 3–5 g/day.
   Mechanism: Phosphocreatine buffer for rapid ATP regeneration. PMC

8. N-acetyl-cysteine (NAC)
   Description: Antioxidant precursor of glutathione; theoretical benefit for oxidative stress.
   Dosage: 600–1200 mg/day.
   Mechanism: Replenishes intracellular glutathione; modulates neuroinflammation (indirect). PMC

9. Curcumin (with piperine for absorption)
   Description: Anti-inflammatory polyphenol; interactions with anticoagulants must be considered.
   Dosage: Varies by formulation; follow product clinical data.
   Mechanism: NF-κB and cytokine modulation (supportive evidence in general inflammation). PMC

10. Resveratrol
    Description: Polyphenol with antioxidant/mitochondrial signaling effects; clinical benefits uncertain but generally well tolerated in food-range doses.
    Dosage: 100–300 mg/day used in studies.
    Mechanism: Sirtuin activation, oxidative stress reduction. PMC

---

Immunity-booster / Regenerative / Stem-cell drugs

There are no FDA-approved immunity “boosters,” regenerative, or stem-cell drugs for SPG78/HSP. Unregulated stem-cell clinics are risky and should be avoided. Research directions include:

1. Lysosome/polyamine pathway modulation for ATP13A2 – Experimental work shows ATP13A2 exports polyamines and protects against lysosomal stress; future small molecules may target this axis. PNAS+1

2. K+ handling and lysosomal function – New mechanistic work suggests ATP13A2 also affects lysosomal K+ homeostasis, pointing to novel targets. Nature

3. Mitochondria-lysosome crosstalk antioxidants – Strategies to reduce ROS from impaired polyamine balance are being studied preclinically. Frontiers

4. Gene therapy concepts – In theory, replacing ATP13A2 or correcting variants is plausible but not in human trials for SPG78 yet. Background biology supports interest. Frontiers

5. Cell-based neurotrophic support – Mesenchymal or neural progenitor cells remain investigational; no proven clinical benefit in HSP. (General spasticity literature only.) PMC

6. Chaperones/protein homeostasis modifiers – Early bench research explores stabilizing ATP13A2 folding/trafficking; clinical translation is pending. rupress.org

---

Surgeries (procedures & why they’re done)

1. Intrathecal Baclofen (ITB) pump implantation
   Procedure: A programmable pump is placed under the abdominal skin with a catheter into the spinal fluid. After a successful screening dose, a surgeon implants the system; refills occur every 1–6 months.
   Why: For severe, generalized spasticity that limits walking, hygiene, or sleep despite therapy/medications. ITB can lower tone, improve comfort, and facilitate function with fewer systemic side effects than high-dose oral agents. PMC+2PubMed+2

2. Selective Dorsal Rhizotomy (SDR)
   Procedure: A neurosurgeon surgically sectiones selected sensory rootlets in the lower spinal cord under neurophysiologic guidance.
   Why: In carefully selected HSP cases with predominant lower-limb spasticity, SDR may reduce tone and improve ambulatory function; evidence is emerging and patient selection is critical. PMC

3. Orthopedic tendon lengthening (e.g., hamstrings, Achilles)
   Procedure: Lengthening contracted tendons with minimally invasive or open techniques, sometimes as part of single-event multilevel surgery.
   Why: To correct fixed knee-flexion or equinus deformity that bracing and therapy cannot overcome, thereby improving step clearance and brace tolerance. PMC

4. Chemodenervation-guided soft tissue procedures
   Procedure: Using prior botulinum toxin response to plan targeted releases or transfers.
   Why: To address focal deforming spastic patterns that resist conservative care and limit function. FDA Access Data

5. Urologic procedures for refractory neurogenic bladder (select cases)
   Procedure: Options range from intradetrusor botulinum toxin injections to bladder augmentation in severe refractory cases.
   Why: Protect kidneys and reduce incontinence burden when medications fail. (Decision individualized in neuro-urology.) FDA Access Data

---

Preventions

1. Daily stretching and posture checks – prevents contractures and pain flares. Physiopedia

2. Strength & balance routine – lowers falls; even short sessions help. PMC

3. Footwear/orthoses maintenance – keeps alignment, reduces tripping. PMC

4. Home safety modifications – grab bars, lighting, remove loose rugs. PMC

5. Bladder program & constipation prevention – protects skin and kidneys. PMC

6. Hydration and heat management – avoid spasticity triggers. PMC

7. Vaccinations and infection prevention – maintain resilience for rehab; infections can worsen spasticity temporarily. PMC

8. Mood/sleep care – earlier treatment prevents functional decline. PMC

9. Regular multidisciplinary follow-up – catches issues early. ScienceDirect

10. Avoid abrupt baclofen changes – withdrawal can be dangerous. FDA Access Data

---

When to see doctors

• New or sudden changes: Rapid worsening of weakness, new falls, sudden severe back pain after a “pop,” new bladder retention, fever with severe spasticity, or sudden confusion—seek urgent evaluation. Abrupt baclofen interruption (oral or pump) is an emergency. FDA Access Data

• Routine: See neurology/rehab at least every 6–12 months (or sooner if function changes) for medication review, therapy updates, and equipment checks. Urology if urinary symptoms rise or UTIs recur; mental-health support for mood/sleep. PMC

---

What to eat and what to avoid

• Eat: (1) Protein with every meal to support muscle (fish, poultry, legumes). (2) High-fiber plants to prevent constipation (vegetables, fruit, oats). (3) Healthy fats with omega-3s (fatty fish, flax/chia) to support general anti-inflammatory balance. (4) Calcium and vitamin D sources for bone health (dairy/fortified alternatives). (5) Adequate fluids spaced through the day to balance bladder urgency/triggers. (6) Magnesium-rich foods (greens, nuts) for cramps (if safe). (7) Iron-rich foods if iron low (with medical guidance). (8) Balanced sodium if dizziness from low BP on meds. (9) Evening snacks that won’t disturb sleep (simple, small, protein-containing). (10) If B12 low (or vegan), include fortified foods & discuss supplements. PMC+2PubMed+2

• Avoid/Limit: Highly processed salty foods if you have bladder irritation or hypertension; excessive caffeine/alcohol that can worsen urgency and sleep; very low-carb dehydration states that tighten muscles; grapefruit with certain meds (check labels); megadose supplements without labs and clinician review.

---

Frequently Asked Questions

1. Is SPG78 the same as all HSP?
   No. HSPs are a large group. SPG78 is linked to ATP13A2 changes and often has additional neurological features. PMC+1

2. How is SPG78 diagnosed?
   By clinical exam and genetic testing confirming two ATP13A2 variants; MRI and nerve tests help rule out other causes. PMC

3. Is there a cure?
   No cure yet. Symptom control and rehabilitation are the standard of care; research targets lysosome/polyamine biology. PMC+1

4. Will therapy really help?
   Yes—programs focused on stretching, strengthening, gait and balance improve function and quality of life. Consistency matters. PMC

5. When are botulinum toxin injections used?
   For focal spasticity patterns that interfere with walking or hygiene despite therapy; effects last ~3 months. FDA Access Data

6. What if my spasticity is severe everywhere?
   An ITB pump may be considered after a successful test dose and goal-setting discussion. FDA Access Data

7. Are bladder problems common?
   Yes; urgency/frequency are common in HSP and respond to bladder training and, if needed, medications. PMC

8. Do I need special shoes or braces?
   Often, yes. Proper footwear and AFOs can reduce tripping and conserve energy. PMC

9. Can diet or vitamins cure SPG78?
   No. Correcting deficiencies (D, B12) supports general health, but supplements are supportive—not curative. PubMed+1

10. Why do some SPG78 patients also have parkinsonism?
    ATP13A2 biology overlaps with pathways in parkinsonism; some individuals benefit from levodopa. OUP Academic

11. Is SDR surgery right for me?
    Only for carefully selected patients with predominant lower-limb spasticity; discuss in a specialist center. PMC

12. Can I exercise safely?
    Yes—start low, go slow, warm up, and cool down; pool or bike can be great options. sp-foundation.org

13. What makes spasticity worse day-to-day?
    Fatigue, infections, pain, sudden stretch, stress, and abrupt medicine changes. FDA Access Data

14. Should my family get tested?
    Genetic counseling is helpful. Parents are carriers; siblings may wish to know their status for planning. PMC

15. What research should I watch?
    Therapies targeting lysosome/polyamine transport and mitochondria–lysosome stress in ATP13A2 disorders. PNAS+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 13, 2025.